Printer Friendly

Islet brain 1 protects insulin producing cells against lipotoxicity.

1. Introduction

Type 2 diabetes is one of the major health challenges of the 21st century. The disease arises when beta cells produce insufficient insulin to meet the increased hormone demand, caused by insulin resistance or growth of tissues such as liver, muscle, and adipose tissues. Although genome-wide association studies revealed a genetic contribution in the etiology of the disease [1], the environmental risks factors are very likely the most prominent cause of beta cell decline in the vast majority of cases [2]. Lifestyle changes such as lack of physical activity together with excessive adiposity contribute to chronic elevation of the circulating plasma saturated free fatty acids (FFAs). Numerous studies have highlighted that chronic exposure to elevated levels of FFAs, in particular palmitate, is detrimental by promoting insulin resistance and beta cell dysfunction [3]. The beta cell failure elicited by palmitate includes a defect in their secretory capacity to respond to glucose and a loss of beta cell mass by apoptosis [4-8]. These diabetogenic effects of palmitate are in part achieved by modulating the expression and activity of proapoptotic and antiapoptotic proteins [3, 9-20].

The mitogen activated protein kinase 8 interacting protein 1, also named islet brain 1 (IB1) or c-Jun N Terminal Kinase- (JNK-) interacting protein 1 (JIP1), is mainly expressed in islet beta cells and is one of the key antiapoptotic factors of this cell type [21-24]. Reduction of the IB1 content in insulin producing and islets cell increases apoptosis [25-27]. A wealth of data reports the diminution of IB1 level, as a major mechanism through which inflammatory cytokines cause beta cell apoptosis [22, 23, 25-29]. Some studies have ascribed the protective role of IB1 to the regulation of JNK pathway, although the exact mechanism of this regulation is still unclear [30, 31]. Reduction of IB1 expression may activate phosphorylation of JNK targets [30]. A mutation within the coding region of this gene has been associated with a rare and monogenic form of diabetes and induces beta cell death in vitro [23].

Conversely, overexpression of IB1 renders cells more resistant to apoptosis induced by cytokines [22, 23, 26, 27, 29]. Moreover, induction of IB1 is a major target of the glucagon-like peptide 1 mimetics for preventing beta cell death [26]. However, the role of IB1 in the context of lipotoxicity has not been reported thus far. In this report, we demonstrated the roles of IB1 in palmitate-induced beta cell death and function and described the regulation of IB1 by palmitate at both the transcriptional and posttranslational levels.

2. Material and Methods

2.1. Materials. Palmitate (sodium salts) was obtained from Sigma-Aldrich (St. Louis, MO). The saturated fatty acid was coupled to bovine serum albumin by1h agitation at 37[degrees]C and freshly prepared for each experiment [32]. This procedure yielded BSA-coupled fatty acids in a molar ratio of 5: 1. The MG132 compound was purchased from Sigma-Aldrich (St. Louis, MO). The antibodies against IB1, mSIN3, and c/ebp[beta] were obtained from Santa Cruz Biotechnology (CA, USA).

2.2. Islets Preparation, Cell Culture, and Transfection. Rat islets were isolated from the pancreas of Sprague-Dawley rats (male, at body weight of 250-350 g) by ductal injection of collagenase. The purification and culture of islets were conducted as described [29]. The mouse insulin-secreting cell line MIN6 was cultured in DMEM glutamax medium (Invitrogen, Carlsbad, CA) supplemented with 15% FCS, 50 U/mL penicillin, 50 [micro]g/mL streptomycin, and 70 [micro]M [beta]-mercaptoethanol [33]. The rat insulin-secreting cell line INS-1E was maintained in RPMI1640 medium supplemented with 10% FCS, 1 mM Sodium Pyruvate, 50 [micro]M [beta]-mercaptoethanol, and 10 mM Hepes [26]. The plasmid encoding HA-IB1-WT and siRNA duplexes directed against IB1 (si-IB1), GFP (si-GFP), or ICER (silCER) were previously described [26, 34]. Plasmids or the siRNA duplexes were introduced using the Lipofectamine 2000 (Invitrogen AG) exactly as described [26].

2.3. Measurement of Insulin Secretion. The MIN6 cells ([10.sup.5]) were plated in 24-well dishes. Two days after transfection, cells were washed twice with PBS. Thereafter, cells were pre-incubated in KRBH buffer (140 mM NaCl, 3.6 mM KCl, 0.5 mM Na[H.sub.2]P[O.sub.4], 0.5 mM MgS[O.sub.4], 1.5 mM Ca[Cl.sub.2], 2mM NaHC[O.sub.3], 10 mM HEPES, 0.1% bovine serum albumin, and pH 7.4) containing 2 mM glucose for 1 hour. Afterward medium was changed with KRBH buffer containing 2 mM glucose corresponding to basal state or with 20 mM glucose for an additional 45 minutes. Insulin secretion was measured by EIA (SPI-BIO) according to manufactured protocol.

2.4. Western Blotting. The cells were scrapped in the PBS and lysed by using a NP-40 lysis buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, and 1% NP-40) supplemented with antiproteases and antiphosphatases (Roche). 25-40 [micro]g of total protein extracts was separated on 10% SDS-polyacrylamide gel and electrically blotted to nitrocellulose membrane. The proteins were detected using a buffer containing 0.1% Tween 20 and 5% milk and incubated overnight at 4[degrees]C with specific primary antibodies and were visualized with IRDye 800 or IRDye 700 (Rockland) as secondary antibodies. Quantification was realized using the Odyssey Infrared Imaging System (Li-COR).

2.5. Reverse Transcription Coupled with Quantitative PCR (RT-qPCR). Total RNA was extracted using guanidium thiocyanate-phenol-chloroform RNA purification method. Reverse transcription was performed as described [34]. Real-time quantitative-PCR assays were carried out on the BioRad MyiQ Real-Time PCR Detection System using iQ SyBr Green Supermix (Bio-Rad) as the amplification system with 100 nM primers and 2 [micro]L of template (RT product) in 20 [micro]L of PCR volume and annealing temperature of 59[degrees]C. Primers sequences were as follows: mouse Ib1, sense 5'-ACA AGG GCA ATG ATG TCC TC-3' and antisense 5'-TTT ATT TCC CTT GGC CTC C-3'; mouse housekeeping ribosomal protein, large P0 (Rplp0), sense 5'-ACCTCCTTC-TTCCAGGCTTT-3' and antisense 5'-CCACCTTGTCTC-CAGTCTTT-3'; mouse Bcl2, sense 5'-CTCCCGATTCAT-TGCAAGTT-3' and antisense 5'-TCTACTTCCTCCGCA-ATGCT-3'.

3. Results

3.1. Reduction of Ib1 Content in MIN6 Cells by Palmitate Relied on the Transcriptional Repressor ICER and Proteasome-Mediated Degradation. A large number of reports have confirmed the adverse effects of palmitate on function and survival of isolated islets and different insulin-secreting cells including MIN6 cells [11,13,15,19]. For this reason we chose to monitor the Ib1 mRNA level in MIN6 cells and isolated rat islets that were cultured with palmitate. RT-qPCR showed reduction of Ib1 mRNA in islet and MIN6 cells cultured with palmitate for 48 and 72hrs (Figure 1(a)). Because palmitate modulates the activity of several transcription factors [11], we tested the hypothesis that the decreased Ib1 mRNA levels resulted from reduced transcriptional activity of its promoter. The human proximal IB1 promoter contains several key elements that promote expression and regulation of the gene in beta cell [35]. A 731 bp fragment of the proximal promoter has been cloned upstream of the luciferase reporter (IB1luc) and is highly active in insulin producing cells [24]. As previously observed, luciferase activity of the IB1-luc construct was 20-25-fold higher than the promoterless control vector in MIN6 cells (Figure 1(b)). This activity was reduced by twofold when the cells were cultured in the presence of palmitate (Figure 1(b)). The IB1 promoter contains a cAMP response element (CRE) [26]. This element binds the inducible cAMP early repressor (ICER) [26], an antagonist of the CRE-binding protein (CREB). ICER expression rises up in beta cells incubated with palmitate [36]. We have previously demonstrated that overexpression of ICER represses the promoter activity of IB1-luc in beta cells [26]. To investigate whether ICER links palmitate to reduced Ib1 mRNA levels, we transfected MIN6 cells with siRNA directed against ICER (siICER) that we previously validated in beta cells [28, 34, 37]. Interestingly, silencing of ICER restored IB1luc activity and Ib1 mRNA levels in the presence of palmitate (Figures 1(b) and 1(c)), supporting a role for ICER in the reduction of Ib1 expression induced by palmitate. Activating transcription factor 3 (ATF3), which also binds to the CRE site, is a potent repressor of gene expression induced by palmitate in beta cells [35, 38, 39]. However, the Ib1 expression was neither reduced in cells in which Atf3 was overexpressed (see supplementary Figure 1a in Supplementary Material available online at 2016/9158562) nor increased in islets cells from atf3 knockout mice, thus ruling out a role for Atf3 in the loss of Ib1 mRNA caused by the saturated fatty acid (supplementary Figure 1b). Two Ib1 isoforms, one corresponding to the full length protein and one from the use of an alternative promoter [26], were detected in MIN6 cells by immunoblotting experiments (Figure 2(a)) [26, 27]. A significant reduction in Ib1 protein levels was apparent after 24 hrs treatment of cells with palmitate (Figure 2(a)). These results were confirmed in isolated rat islets cultured with palmitate for 24 hrs (Figure 2(b)). Palmitate hampers insulin expression, secretion, and cell survival by inducing the expression of C/EBP[ss] [11]. Interestingly we observed that the decreased Ib1 protein level was concomitant with the increased C/EBP[ss] protein levels (Figures 2(a) and 2(b)). Chronic hyperglycemia potentiates the harmful effects of palmitate [9] in INS-1E cells but not in MIN6 or isolated human islets [40]. To determine whether the effects of palmitate were potentiated by glucose, Ib1 protein levels were quantified in INS-1E cells cultured with palmitate in the presence of low or high glucose concentration (5 or 20 mmol/L glucose, resp.). A similar reduction of Ib1 by palmitate was observed upon low or high glucose concentration (Figure 2(c)), indicating that palmitate decreases the expression of high glucose concentration. Since decreased Ib1 protein levels occurred prior to the decrease of its mRNA levels (Figures 1(a) and 2(a)), this suggests that the reduction of Ib1 mRNA is not the only mechanism affecting its protein content. The fatty acid affects beta cell survival and function through ER stress dependent pathways [3, 15-17]. Palmitate impairs [Ca.sup.2+] influx to ER by affecting sarcoendoplasmic-reticulum pump [Ca.sup.2+]-ATPase (SERCA), also known as ATP2A2 activity [19]. Defective cytosolic [Ca2.sup.+] leads to proteasome-mediated degradation [41]. To test the hypothesis that the loss of Ib1 content involves proteasome, MIN6 cells were coincubated with palmitate and the proteasome inhibitor MG132. Treatment of cells with this chemical compound efficiently restored Ib1 protein levels in the presence of palmitate (Figure 3(a)). In addition, thapsigargin (thaps), an ER stress inducer that promotes [Ca.sup.2+]-induced degradation evoked by proteasome [42], reduced Ib1 protein content in MIN6 and INS-1E cells (Figure 3(b)). Under these experimental conditions, MG132 treatment efficiently restored Ib1 protein level in the presence of thaps (Figure 3(b)).

3.2. Overexpression of Ib1 Counteracts the Deleterious Effects of Palmitate on Glucose-Induced Insulin Secretion and Cell Survival. IB1 is required for glucose-induced insulin secretion and cell survival [23, 26, 43]. We investigated whether the decreased Ib1 level contributes to palmitate-induced cell death by ectopically expressing Ib1. As shown in Figures 4(a) and 4(b), IB1 partially rescued the cells as evidenced by the reduction in apoptotic cell number and increase in the mRNA level of Bcl2, an antiapoptotic gene. Conversely, silencing of Ib1 using a previously validated siRNA [26] potentiated the effect of palmitate on cell death (Figure 4(a)) with a concomitant increase of the Bcl2 mRNA (Figure 4(b)). We next investigated whether the reduction of Ib1 by palmitate could contribute to defective glucose-induced insulin secretion. As previously shown [43], silencing of Ib1 in Min6 cells reduced glucose-induced insulin secretion (Figure 5), which was exacerbated in the presence of palmitate (Figure 5). Transient ectopic expression of Ib1 can overcome proteasome-mediated degradation of Ib1 elicited by cytokines [22, 23, 27, 44]. It has been previously shown that Ib1 overexpressing beta cells are more resistant to apoptosis [22, 23, 27, 44]. Interestingly and in line with these observations, Ib1 overexpressing Min6 cells improved their glucose-induced insulin secretion when chronically exposed to palmitate (Figure 5).

4. Discussion

Evidence for the potential diabetogenic role of palmitate by afflicting beta cell function and survival has been provided by a plethora of data from in vitro and in vivo experiments [3, 7, 12, 41]. Palmitate decreases beta cell survival by promoting apoptosis [19]. Reduction of the antiapoptotic IB1 expression is a major mechanism eliciting beta cell apoptosis in response to cytokines and oxidized LDL [25, 26, 28, 29]. However, its role in lipotoxicity has not been reported. In this report, we show that palmitate decreases Ib1 gene expression at both the transcriptional and posttranslational levels. At the transcriptional level, the effect is dependent on the transcriptional repressor ICER, since silencing of ICER dampened the ability of palmitate to reduce Ib1 mRNA. Although the level of ATF3, another transcriptional repressor, is increased by palmitate [39], our data indicate that ATF3 is not necessary for palmitate to repress Ib1 gene expression. Interestingly, our data showed that diminution of IB1 protein content occurs earlier than the drop of Ib1 mRNA and this was via a proteasome-mediated pathway. Overexpression of Ib1 protects beta cell against apoptosis triggered by cytokines [22, 25]. In line with this protective effect we observed that ectopic expression of Ib1 prevented the deleterious effect of palmitate on cell survival.

Beside its antiapoptotic role, Ib1 regulates glucose-induced insulin secretion [21, 23, 43]. Consistent with this metabolic function, inactivation of Ib1 alters insulin secretion stimulated by glucose [43]. Herein we confirmed that silencing of Ib1 mimics the effect of palmitate on insulin secretion. Moreover, ectopic expression of Ib1 partially restored glucose-induced insulin secretion in response to palmitate, indicating that exogenous expression of Ib1 compensates for the decrease of Ib1 content caused by palmitate. Ib1 is described as a scaffold protein that assembles the kinases involved in the JNK activation; however, paradoxically its function is to inhibit JNK activity [22, 25, 26, 29, 31]. JNK activation often (but not always) precedes JNK activity. The c-Jun transcription factor is a JNK target that is deemed to couple JNK activation to apoptosis [45]. JNK phosphorylates c-Jun and this could lead to apoptosis [45, 46]. Independent studies have shown that Ib1 level may be required for inhibiting phosphorylation of c-Jun [25, 27]. Overexpression of Ib1 level reduces phosphorylation of c-Jun caused by cytokines in islets and insulin producing cells [25, 27].

JNK pathway is activated in response to several diabetogenic stresses including oxidized LDL and cytokines [26, 29]. Increased JNK activity is a key mechanism coupling palmitate to beta cell dysfunction and ultimately cell death [3, 19], and inhibition of JNK activity alleviates the adverse effects of palmitate [3, 19]. ttus, our finding that palmitate reduces Ib1 expression may provide a potential mechanism for palmitate to increase JNK activity. There are three JNK isoforms identified so far [47]. All of them are present in beta cells [48]. There are growing studies pointing to divergent roles in JNK isoforms in beta cells. While JNK2 seems to be proapoptotic, JNK1 and JNK3 are antiapoptotic [4850]. tterefore, further analyses are required to determine whether and how Ib1 may regulate each of the JNK isoforms. Understanding such regulation will permit us to elucidate the mechanism through which IB1 preserves beta cell against the harmful effects caused by palmitate. Inhibition of the JNK pathway has been proposed as a potential therapeutic way for treating beta cell failure in type 2 diabetes and some efforts are currently maintained to identify novel JNK inhibitors [51]. Future investigation of IB1 activity may help in finding out novel targets exploitable in the design of next innovative therapies of T2D.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors' Contribution

Saska Brajkovic, Mourad Ferdaoussi, and Valerie Pawlowski equally contributed to the work.


This work was supported by the Chair of Excellence from the French National Agency for Research no. ANR-10-CEXC-005-01, the Regional Council Nord Pas de Calais, and the European Regional Development Fund. This work was also supported by grants from "European Genomic Institute for Diabetes" (E.G.I.D., ANR-10-LABX-46) and European Commission. tte authors are grateful to Mr. Raphael Boutry and Mrs. Laure Rolland for editorial and technical assistance.


[1] A. Bonnefond, P. Froguel, and M. Vaxillaire, "The emerging genetics of type 2 diabetes," Trends in Molecular Medicine, vol. 16, no. 9, pp. 407-416, 2010.

[2] X. Lin, K. Song, N. Lim et al., "Risk prediction of prevalent diabetes in a Swiss population using a weighted genetic score--the CoLaus Study," Diabetologia, vol. 52, no. 4, pp. 600-608, 2009.

[3] M. Cnop, L. Ladriere, M. Igoulo-Esteve, R. F. Moura, and D. A. Cunha, "Causes and cures for endoplasmic reticulum stress in lipotoxic [beta]-cell dysfunction," Diabetes, Obesity and Metabolism, vol. 12, supplement 2, pp. 76-82, 2010.

[4] J. J. Meier, T. G. K. Breuer, R. C. Bonadonna et al., "Pancreatic diabetes manifests when beta cell area declines by approximately 65% in humans," Diabetologia, vol. 55, no. 5, pp. 1346-1354, 2012.

[5] A. E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R. A. Rizza, and P. C. Butler, "[beta]-cell deficit and increased [beta]-cell apoptosis in humans with type 2 diabetes," Diabetes, vol. 52, no. 1, pp. 102-110, 2003.

[6] M. Y. Donath, D. M. Schumann, M. Faulenbach, H. Ellingsgaard, A. Perren, and J. A. Ehses, "Islet inflammation in type 2 diabetes: from metabolic stress to therapy," Diabetes Care, vol. 31, supplement 2, pp. S161-S164, 2008.

[7] K. Eguchi, I. Manabe, Y. Oishi-Tanaka et al., "Saturated fatty acid and TLR signaling link [beta] cell dysfunction and islet inflammation," Cell Metabolism, vol. 15, no. 4, pp. 518-533, 2012.

[8] M. B. Hoppa, S. Collins, R. Ramracheya et al., "Chronic palmitate exposure inhibits insulin secretion by dissociation of [Ca.sup.2+] channels from secretory granules," Cell Metabolism, vol. 10, no. 6, pp. 455-465, 2009.

[9] V. Poitout, "Glucolipotoxicity of the pancreatic [beta]-cell: Myth or reality?" Biochemical Society Transactions, vol. 36, no. 5, pp. 901-904, 2008.

[10] K. Maedler, G. A. Spinas, D. Dyntar, W. Moritz, N. Kaiser, and M. Y. Donath, "Distinct effects of saturated and monounsaturated fatty acids on [beta]-cell turnover and function," Diabetes, vol. 50, no. 1, pp. 69-76, 2001.

[11] V. Plaisance, V. Perret, D. Favre et al., "Role of the transcriptional factor C/EBPbeta in free fatty acid-elicited beta-cell failure," Molecular and Cellular Endocrinology, vol. 305, no. 1-2, pp. 47-55, 2009.

[12] S. Kashyap, R. Belfort, A. Gastaldelli et al., "A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes," Diabetes, vol. 52, no. 10, pp. 2461-2474, 2003.

[13] M. L. Watson, K. Macrae, A. E. Marley, and H. S. Hundal, "Chronic effects of palmitate overload on nutrient-induced insulin secretion and autocrine signalling in pancreatic MIN6 beta cells," PLoS ONE, vol. 6, no. 10, Article ID e25975, 2011.

[14] D. K. Hagman, M. G. Latour, S. K. Chakrabarti et al., "Cyclical and alternating infusions of glucose and intralipid in rats inhibit insulin gene expression and Pdx-1 binding in islets," Diabetes, vol. 57, no. 2, pp. 424-431, 2008.

[15] M. C. Akerfeldt, J. Howes, J. Y. Chan et al., "Cytokine-Induced [beta]-cell death is independent of endoplasmic reticulum stress signaling," Diabetes, vol. 57, no. 11, pp. 3034-3044, 2008.

[16] I. Kharroubi, L. Ladriere, A. K. Cardozo, Z. Dogusan, M. Cnop, and D. L. Eizirik, "Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms: role of nuclear factor-kappaB and endoplasmic reticulum stress," Endocrinology, vol. 145, no. 11, pp. 5087-5096, 2004.

[17] D. R. Laybutt, A. M. Preston, M. C. Akerfeldt et al., "Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes," Diabetologia, vol. 50, no. 4, pp. 752-763, 2007.

[18] S.-M. Lee, S.-E. Choi, J.-H. Lee et al., "Involvement of the TLR4 (Toll-like receptor4) signaling pathway in palmitate-induced INS-1 beta cell death," Molecular and Cellular Biochemistry, vol. 354, no. 1-2, pp. 207-217, 2011.

[19] D. A. Cunha, P. Hekerman, L. Ladriere et al., "Initiation and execution of lipotoxic ER stress in pancreatic [beta]-cells," Journal of Cell Science, vol. 121, no. 14, pp. 2308-2318, 2008.

[20] K. Tanabe, Y. Liu, S. D. Hasan et al., "Glucose and fatty acids synergize to promote B-cell apoptosis through activation of glycogen synthase kinase 3[beta] independent of JNK activation," PLoS ONE, vol. 6, no. 4, Article ID e18146, 2011.

[21] C. Bonny, P. Nicod, and G. Waeber, "IB1, a JIP-1-related nuclear protein present in insulin-secreting cells," Journal of Biological Chemistry, vol. 273, no. 4, pp. 1843-1846,1998.

[22] C. Bonny, A. Oberson, M. Steinmann, D. F. Schorderet, P. Nicod, and G. Waeber, "IB1 reduces cytokine-induced apoptosis of insulin-secreting cells," The Journal of Biological Chemistry, vol. 275, no. 22, pp. 16466-16472, 2000.

[23] G. Waeber, J. Delplanque, C. Bonny et al., "The gene MAPK8IP1, encodingislet-brain-1, is a candidate for type 2 diabetes," Nature Genetics, vol. 24, no. 3, pp. 291-295, 2000.

[24] A. Abderrahmani, M. Steinmann, V Plaisance et al., "The transcriptional repressor REST determines the cell-specific expression of the human MAPK8IP1 gene encoding IB1 (JIP-1)," Molecular and Cellular Biology, vol. 21, no. 21, pp. 7256-7267, 2001.

[25] Z. Ling, M. Van de Casteele, J. Donget al., "Variations in IB1/JIP1 expression regulate susceptibility of beta-cells to cytokine-induced apoptosis irrespective of c-Jun NH2-terminal kinase signaling," Diabetes, vol. 52, no. 10, pp. 2497-2502, 2003.

[26] M. Ferdaoussi, S. Abdelli, J.-Y. Yang et al., "Exendin-4 protects [beta]-cells from interleukin-1[beta]-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway," Diabetes, vol. 57, no. 5, pp. 1205-1215, 2008.

[27] J.-A. Haefliger, T. Tawadros, L. Meylan et al., "The scaffold protein IB1/JIP-1 is a critical mediator of cytokine-induced apoptosis in pancreatic [beta] cells," Journal of Cell Science, vol. 116, no. 8, pp. 1463-1469, 2003.

[28] D. Favre, G. Niederhauser, D. Fahmi et al., "Role for inducible cAMP early repressor in promoting pancreatic beta cell dysfunction evoked by oxidative stress in human and rat islets," Diabetologia, vol. 54, no. 9, pp. 2337-2346, 2011.

[29] A. Abderrahmani, G. Niederhauser, D. Favre et al., "Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells," Diabetologia, vol. 50, no. 6, pp. 1304-1314, 2007.

[30] N. Beeler, B. M. Riederer, G. Waeber, and A. Abderrahmani, "Role of the JNK-interacting protein 1/islet brain 1 in cell degeneration in Alzheimer disease and diabetes," Brain Research Bulletin, vol. 80, no. 4-5, pp. 274-281, 2009.

[31] M. Dickens, J. S. Rogers, J. Cavanagh et al., "A cytoplasmic inhibitor of the JNK signal transduction pathway," Science, vol. 277, no. 5326, pp. 693-696,1997.

[32] A. K. Busch, D. Cordery, G. S. Denyer, and T. J. Biden, "Expression profiling of palmitate- and oleate-regulated genes provides novel insights into the effects of chronic lipid exposure on pancreatic [beta]-cell function," Diabetes, vol. 51, no. 4, pp. 977-987, 2002.

[33] V. Lilla, G. Webb, K. Rickenbach et al., "Differential gene expression in well-regulated and dysregulated pancreatic beta-cell (MIN6) sublines," Endocrinology, vol. 144, no. 4, pp. 1368-1379, 2003.

[34] D. Favre, E. Le Gouill, D. Fahmi et al., "Impaired expression of the inducible cAMP early repressor accounts for sustained adipose CREB activity in obesity," Diabetes, vol. 60, no. 12, pp. 3169-3174, 2011.

[35] T. Hai, C. D. Wolfgang, D. K. Marsee, A. E. Allen, and U. Sivaprasad, "ATF3 and stress responses," Gene Expression, vol. 7, no. 4-6, pp. 321-335, 1999.

[36] Y.-P. Zhou, K. Marlen, J. F. Palma et al., "Overexpression of repressive cAMP response element modulators in high glucose and fatty acid-treated rat islets: a common mechanism for glucose toxicity and lipotoxicity?" The Journal of Biological Chemistry, vol. 278, no. 51, pp. 51316-51323, 2003.

[37] A. Abderrahmani, S. Cheviet, M. Ferdaoussi, T. Coppola, G. Waeber, and R. Regazzi, "ICER induced by hyperglycemia represses the expression of genes essential for insulin exocytosis," EMBO Journal, vol. 25, no. 5, pp. 977-986, 2006.

[38] E. J. Zmuda, L. Qi, M. X. Zhu, R. G. Mirmira, M. R. Montminy, and T. Hai, "The roles of ATF3, an adaptive-response gene, in high-fat-diet-induced diabetes and pancreatic beta-cell dysfunction," Molecular Endocrinology, vol. 24, no. 7, pp. 1423-1433, 2010.

[39] M. G. Hartman, D. Lu, M.-L. Kim et al., "Role for activating transcription factor 3 in stress-induced [beta]-cell apoptosis," Molecular and Cellular Biology, vol. 24, no. 13, pp. 5721-5732, 2004.

[40] E. Sargsyan and P. Bergsten, "Lipotoxicity is glucose-dependent in INS-1E cells but not in human islets and MIN6 cells," Lipids in Health and Disease, vol. 10, article 115, 2011.

[41] T. J. Biden, E. Boslem, K. Y. Chu, and N. Sue, "Lipotoxic endoplasmic reticulum stress, beta cell failure, and type 2 diabetes mellitus," Trends in Endocrinology and Metabolism, vol. 25, no. 8, pp. 389-398, 2014.

[42] H. Zhang, H. Hoff, and C. Sell, "Downregulation of IRS-1 protein in thapsigargin-treated human prostate epithelial cells," Experimental Cell Research, vol. 289, no. 2, pp. 352-358, 2003.

[43] O. Kristensen, S. Guenat, I. Dar et al., "A unique set of SH3-SH3 interactions controls IB1 homodimerization," EMBO Journal, vol. 25, no. 4, pp. 785-797, 2006.

[44] N. Allaman-Pillet, J. Storling, A. Oberson et al., "Calcium- and proteasome-dependent degradation of the JNK scaffold protein islet-brain 1," Journal of Biological Chemistry, vol. 278, no. 49, pp. 48720-48726, 2003.

[45] S. Zhang, J. Liu, G. MacGibbon, M. Dragunow, and G. J. S. Cooper, "Increased expression and activation of c-Jun contributes to human amylin-induced apoptosis in pancreatic islet [beta]-cells," Journal of Molecular Biology, vol. 324, no. 2, pp. 271-285, 2002.

[46] C. R. Weston and R. J. Davis, "The JNK signal transduction pathway," Current Opinion in Cell Biology, vol. 19, no. 2, pp. 142-149, 2007.

[47] E. T. Coffey, "Nuclear and cytosolic JNK signalling in neurons," Nature Reviews Neuroscience, vol. 15, no. 5, pp. 285-299, 2014.

[48] S. Abdelli, J. Puyal, C. Bielmann et al., "JNK3 is abundant in insulin-secreting cells and protects against cytokine-induced apoptosis," Diabetologia, vol. 52, no. 9, pp. 1871-1880, 2009.

[49] H. Ezanno, V Pawlowski, S. Abdelli et al., "JNK3 is required for the cytoprotective effect of exendin 4," Journal of Diabetes Research, vol. 2014, Article ID 814854, 5 pages, 2014.

[50] M. Prause, D. P. Christensen, N. Billestrup, and T. Mandrup-Poulsen, "JNK1 protects against glucolipotoxicity-mediated beta-cell apoptosis," PLoS ONE, vol. 9, no. 1, Article ID e87067, 2014.

[51] M. A. Bogoyevitch, K. R. W. Ngoei, T. T. Zhao, Y. Y. C. Yeap, and D. C. H. Ng, "c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges," Biochimica et Biophysica Acta-Proteins and Proteomics, vol. 1804, no. 3, pp. 463-475, 2010.

Saska Brajkovic, (1, 2) Mourad Ferdaoussi, (1, 2, 3) Valerie Pawlowski, (2, 4) Helene Ezanno, (2) Valerie Plaisance, (2) Erik Zmuda,(5) Tsonwin Hai, (5) Jean-Sebastien Annicotte, (2) Gerard Waeber, (1) and Amar Abderrahmani (2)

(1) Service of Internal Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, 1011 Lausanne, Switzerland

(2) University of Lille, European Genomic Institute for Diabetes (EGID) FR 3508, UMR CNRS 8199, Faculty of Medicine West, 1 place de Verdun, 59045 Lille, France

(3) Department of Pharmacology and the Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada

(4) University of Lille, EGID FR 3508, Department of Endocrine Surgery, Lille University Hospital, UMR INSERM 1190, Lille, France

(5) Department of Molecular and Cellular Biochemistry, Ohio State University, 1060 Carmack Road, Columbus, OH, USA

Correspondence should be addressed to Amar Abderrahmani;

Received 6 January 2015; Accepted 6 March 2015

Academic Editor: Li Chen
COPYRIGHT 2015 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Brajkovic, Saska; Ferdaoussi, Mourad; Pawlowski, Valerie; Ezanno, Helene; Plaisance, Valerie; Zmuda,
Publication:Journal of Diabetes Research
Date:Jan 1, 2015
Previous Article:Increased DNA dicarbonyl glycation and oxidation markers in patients with type 2 diabetes and link to diabetic nephropathy.
Next Article:Estrogen: an emerging regulator of insulin action and mitochondrial function.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters